PAXMYRNA Trademark

Trademark Overview

On Tuesday, September 8, 2020, a trademark application was filed for PAXMYRNA with the United States Patent and Trademark Office. The USPTO has given the PAXMYRNA trademark a serial number of 90165943. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, March 4, 2024. This trademark is owned by Sanofi Pasteur Inc.. The PAXMYRNA trademark is filed in the Pharmaceutical Products category with the following description:

Vaccines for the prevention of COVID-19
paxmyrna

General Information

Serial Number90165943
Word MarkPAXMYRNA
Filing DateTuesday, September 8, 2020
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, March 4, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, December 8, 2020

Trademark Statements

Goods and ServicesVaccines for the prevention of COVID-19
Pseudo MarkPAX MYRNA

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, October 14, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameSanofi Pasteur Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSwiftwater, PA 18370
Party NameSanofi Pasteur Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSwiftwater, PA 18370

Trademark Events

Event DateEvent Description
Monday, March 4, 2024ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED
Monday, March 4, 2024ABANDONMENT - NO USE STATEMENT FILED
Friday, June 30, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, June 29, 2023SOU EXTENSION 5 GRANTED
Tuesday, June 20, 2023SOU EXTENSION 5 FILED
Thursday, June 29, 2023CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, June 20, 2023SOU TEAS EXTENSION RECEIVED
Thursday, January 5, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, January 3, 2023SOU EXTENSION 4 GRANTED
Tuesday, January 3, 2023SOU EXTENSION 4 FILED
Tuesday, January 3, 2023SOU TEAS EXTENSION RECEIVED
Saturday, June 25, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, June 23, 2022SOU EXTENSION 3 GRANTED
Thursday, June 23, 2022SOU EXTENSION 3 FILED
Thursday, June 23, 2022SOU TEAS EXTENSION RECEIVED
Saturday, January 22, 2022NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, January 20, 2022SOU EXTENSION 2 GRANTED
Thursday, January 20, 2022SOU EXTENSION 2 FILED
Thursday, January 20, 2022SOU TEAS EXTENSION RECEIVED
Thursday, July 15, 2021NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, July 13, 2021SOU EXTENSION 1 GRANTED
Tuesday, July 13, 2021SOU EXTENSION 1 FILED
Tuesday, July 13, 2021SOU TEAS EXTENSION RECEIVED
Tuesday, February 2, 2021NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, December 8, 2020OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, December 8, 2020PUBLISHED FOR OPPOSITION
Wednesday, November 18, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, November 5, 2020APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, November 4, 2020ASSIGNED TO EXAMINER
Wednesday, November 4, 2020PETITION TO DIRECTOR GRANTED
Sunday, November 1, 2020ASSIGNED TO PETITION STAFF
Wednesday, October 28, 2020TEAS PETITION TO DIRECTOR RECEIVED
Tuesday, October 27, 2020TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED
Tuesday, October 27, 2020TEAS VOLUNTARY AMENDMENT RECEIVED
Wednesday, October 14, 2020NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, September 18, 2020TEAS VOLUNTARY AMENDMENT RECEIVED
Friday, September 11, 2020NEW APPLICATION ENTERED

Related Keywords

paxmyrna covid prevention vaccines